financetom
Business
financetom
/
Business
/
Arcadium Lithium Expects to More Than Double Sales Volumes by 2028
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Arcadium Lithium Expects to More Than Double Sales Volumes by 2028
Sep 20, 2024 11:30 AM

11:48 AM EDT, 09/20/2024 (MT Newswires) -- Arcadium Lithium ( ARLTF ) said Thursday it is launching expansion programs that are expected to "more than double" sales volumes by 2028.

"We have a clear and compelling plan to deliver significant growth over the coming years, leveraging the size and quality of our portfolio of assets and expansion projects," Arcadium Chief Executive Paul Graves said. "This plan has the potential to double our sales volumes by 2028 while reaching an expected $1.3 billion in Adjusted EBITDA based on analyst consensus pricing forecasts."

Shares of the company rose over 1% in recent trading.

Price: 2.54, Change: +0.04, Percent Change: +1.40

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Renalys Pharma to be Acquired by Chugai Pharmaceutical
Renalys Pharma to be Acquired by Chugai Pharmaceutical
Oct 24, 2025
TOKYO, Oct. 24, 2025  /PRNewswire/ -- Renalys Pharma, Inc. and Chugai Pharmaceutical Co., Ltd. today announced a definitive stock purchase agreement, under which Chugai will acquire Renalys (the Transaction).  Renalys is advancing sparsentan in Japan; the medicine was initially developed by Travere Therapeutics, Inc. (Travere) and is approved in the United States and Europe for the treatment of IgA nephropathy....
Minerals Technologies Q3 Adjusted Earnings, Sales Rise
Minerals Technologies Q3 Adjusted Earnings, Sales Rise
Oct 24, 2025
03:46 AM EDT, 10/24/2025 (MT Newswires) -- Minerals Technologies ( MTX ) reported late Thursday Q3 earnings excluding special items of $1.55 per diluted share, up from $1.51 per share a year earlier. Three analysts polled by FactSet expected $1.46 per share. Sales for the quarter ended Sept. 28 were $532.4 million, up from $524.7 million a year earlier. Three...
Nanobiotix Transfers Nanoray-312 Sponsorship to Johnson & Johnson
Nanobiotix Transfers Nanoray-312 Sponsorship to Johnson & Johnson
Oct 24, 2025
04:11 AM EDT, 10/24/2025 (MT Newswires) -- Nanobiotix ( NBTX ) said Friday it has transferred Nanoray-312 sponsorship to Johnson & Johnson ( JNJ ) , including the transfer of operational control of the phase 3 head and neck cancer study. The company expects that Nanoray-312, which started in Q3 2024, interim data will be analyzed and reported in H1...
GSK Says US FDA Approves Multiple Myeloma Treatment Combination
GSK Says US FDA Approves Multiple Myeloma Treatment Combination
Oct 24, 2025
03:53 AM EDT, 10/24/2025 (MT Newswires) -- GSK (GSK) said late Thursday the US Food and Drug Administration has approved its Blenrep drug in combination with bortezomib and dexamethasone for the treatment of certain adults with relapsed or refractory multiple myeloma. The approval was supported by data from a phase 3 trial in which the drug combination showed a 51%...
Copyright 2023-2026 - www.financetom.com All Rights Reserved